- Home
- AMTB vs SLS Comparison
AMTB vs SLS Comparison
Compare AMTB & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMTB | SLS |
|---|---|---|
| Founded | 1979 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 922.1M | 924.5M |
| IPO Year | 2018 | 2007 |
Fundamental Metrics
Financial Performance| Metric | AMTB | SLS |
|---|---|---|
| Price | $22.35 | $7.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $23.67 | $10.00 |
| AVG Volume (30 Days) | 202.2K | ★ 6.7M |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.57% | N/A |
| EPS Growth | ★ 386.36 | 50.00 |
| EPS | ★ 0.44 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.29 | N/A |
| Revenue Next Year | $7.67 | $110.98 |
| P/E Ratio | $51.17 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.62 | $1.39 |
| 52 Week High | $24.38 | $9.10 |
Technical Indicators
Market Signals| Indicator | AMTB | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 43.49 | 62.88 |
| Support Level | $21.98 | $3.72 |
| Resistance Level | $22.75 | N/A |
| Average True Range (ATR) | 0.60 | 0.65 |
| MACD | -0.10 | 0.29 |
| Stochastic Oscillator | 46.41 | 62.93 |
Price Performance
Historical ComparisonAbout AMTB Amerant Bancorp Inc.
Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.